DexCom
DXCM
321 hedge funds and large institutions have $7.78B invested in DexCom in 2017 Q1 according to their latest regulatory filings, with 58 funds opening new positions, 100 increasing their positions, 123 reducing their positions, and 45 closing their positions.
39% more capital invested
Capital invested by funds: $5.58B → $7.78B (+$2.2B)
29% more first-time investments, than exits
New positions opened: 58 | Existing positions closed: 45
2% more funds holding
Funds holding: 316 → 321 (+5)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
16.14% less ownership
Funds ownership: 442.4% → 426.27% (-16%)
19% less repeat investments, than reductions
Existing positions increased: 100 | Existing positions reduced: 123
96% less call options, than puts
Call options by funds: $25.3M | Put options by funds: $580M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$318M |
| 2 |
Bank of New York Mellon
New York
|
+$150M |
| 3 |
SPC
Slate Path Capital
New York
|
+$87.4M |
| 4 |
JP Morgan Chase
New York
|
+$73M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$64.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Brown Advisory
Baltimore,
Maryland
|
-$161M |
| 2 |
FAM
Fred Alger Management
New York
|
-$89.5M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$61.2M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$56.4M |
| 5 |
Wells Fargo
San Francisco,
California
|
-$41.5M |
DXCM Hedge Fund Activity: Q1 2017 in Review
321 of the 4,034 institutional investors tracked by Wall St. Rank reported a position in DexCom (DXCM) for Q1 2017, worth a combined $7.78B — up 39% from $5.58B a quarter earlier.
Buyers outnumbered sellers: 58 funds opened new DXCM positions and 45 closed out — a net gain of 13 holders — while 100 added to existing stakes and 123 trimmed.
The largest buyer was BlackRock, adding an estimated $318M. The largest seller was Brown Advisory, cutting an estimated $161M.
- 321 institutional investors held DexCom (DXCM) as of Q1 2017, up from 316 in Q4 2016.
- Funds reported $7.78B of DexCom stock for Q1 2017, up 39% quarter-over-quarter.
- 58 funds opened new DexCom positions in Q1 2017 and 45 closed out, a net change of +13 holders.
- The largest DexCom buyer in Q1 2017 was BlackRock, an estimated $318M added.
- The largest DexCom seller in Q1 2017 was Brown Advisory, an estimated $161M sold.
Based on aggregated 13F filings for Q1 2017.